Estradiol Concentrations for Adequate Gender-Affirming Feminizing Therapy: A Systematic Review
Open Access
- 1 October 2025
- journal article
- review article
- Published by SAGE Publications in LGBT Health
- Vol. 12 (7) , 477-489
Abstract
Purpose: Guidelines recommend serum estradiol concentrations of 100–200 pg/mL for transgender women prescribed oral, subcutaneous, or transdermal estradiol with or without adjunct antiandrogen as gender-affirming feminizing hormone therapy (HT). The purpose of this systematic review was to evaluate if the guideline range of 100–200 pg/mL for estradiol concentration is associated with indicators of adequate gender-affirming feminizing HT, specifically feminizing sufficiency, insufficiency, testosterone suppression, or toxicity in transgender women. Methods: The Populations/Intervention/Comparator/Outcome model was applied to the study question, whereby the target population included transgender, gender-diverse, and nonbinary adults using gender-affirming feminizing HT by any route of administration, with or without adjunct antiandrogen use. The comparator was defined as estradiol concentrations within (100–200 pg/mL or 367–734 pM) versus outside (100–200 pg/mL) the guideline range; evaluated outcomes were listed by the same clinical guidelines that recommend using the 100–200 pg/mL range. Embase, MEDLINE, and Web of Science were queried over a 24-year time frame (January 1, 1999–April 20, 2023); the search was restricted to English. The extracted outcomes were categorized as indicators of therapeutic insufficiency, sufficiency, toxicity, or hormone concentration. Results: There were 49 studies that met the inclusion criteria, of which 9, 42, 25, and 5 studies included indicators of therapeutic insufficiency, sufficiency, toxicity, or hormone concentration, respectively. The search did not identify articles demonstrating that the 100–200 pg/mL guideline range provides optimal feminizing outcomes or reduces adverse events. Conclusions: : Evidence does not support using the guideline range of 100–200 pg/mL to indicate sufficient feminization in transgender women using gender-affirming feminizing HT.Keywords
This publication has 72 references indexed in Scilit:
- The Women’s Health Initiative Randomized Trials and Clinical PracticeJAMA, 2024
- Accuracy-based proficiency testing for estradiol measurementsClinical Biochemistry, 2023
- The Effect of Gender-Affirming Hormone Therapy on Serum Creatinine in Transgender IndividualsEndocrine Practice, 2022
- Fracture risk assessment in an Italian group of transgender women after gender-confirming surgeryJournal of Bone and Mineral Metabolism, 2020
- Risk‐of‐bias VISualization (robvis): An R package and Shiny web app for visualizing risk‐of‐bias assessmentsResearch Synthesis Methods, 2020
- Estradiol reference intervals in women during the menstrual cycle, postmenopausal women and men using an LC-MS/MS methodClinica Chimica Acta, 2019
- Gender-Affirming Hormone Treatment Decreases Bone Turnover in Transwomen and Older TransmenJournal of Bone and Mineral Research, 2019
- Hematology reference intervals for transgender adults on stable hormone therapyClinica Chimica Acta, 2019
- Quality of life and hormones after sex reassignment surgeryJournal of Endocrinological Investigation, 2015
- Preservation of volumetric bone density and geometry in trans women during cross-sex hormonal therapy: a prospective observational studyOsteoporosis International, 2014